Would you use tucatinib in a patient with recurrent HER2+ breast cancer with isolated brain metastasis with leptomeningeal disease?

I certainly would, given the CNS activity seen in the HER2CLIMB trial. I would follow the same paradigm and combine it with capecitabine and trastuzumab.